An update on development of galeterone in the treatment of mCRPC

In a statement from Tokai Pharmaceuticals, the company has provided additional information about the clinical development of the investigational drug galeterone in treatment of metastatic, castration resistant prostate cancer (mCRPC). … READ MORE …

Clinical and therapeutic histories of men who actually die of mCRPC

Despite all the prostate cancer research over the past 30 or so years, we still have limited information about the clinical and therapeutic history of prostate cancer in men who have progressive disease and go on to die of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Update on late stage, “intermediate atypical” mCRPC

According to a report this morning on the UroToday web site, Dr. Eric Small presented an update yesterday on so-called “intermediate atypical”, metastatic, castration-resistant prostate cancer (mCRPC) — at a general session of the 2015 meeting of the Society of Urologic Oncology in Washington, DC. … READ MORE …

Can the ex-Aragon team pull off a repeat with another new drug for mCRPC

According to an article by Alex Lash on the Xconomy web site, a start-up biotech company in South San Francisco called ORIC Pharmaceuticals will — at least initially — be highly focused on new drug therapies for men with very late-stage prostate cancer. … READ MORE …

Published data on activity of olaparib in some men with mCRPC

A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >

Is there ANY role for estramustine phosphate in treatment of CRPC today?

The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,366 other followers